Envelope (E) protein

2022 total revenue of $723 million, up 64% from $439 million in 2021 HEPLISAV-B® vaccine net product revenue of $126 million, representing 104% growth compared to 2021 CpG 1018® adjuvant vaccine net product revenue of $588 million 2023 HEPLISAV-B net product revenue anticipated to be between $165 million and $185 million, representing year-over-year revenue growth of approximately 30-47% Increased strength of financial position with year-end cash and investments of $624 million Conference call today at 4:30 p.m. ET/1:30 p.m. PT EMERYVILLE, Calif., Feb. 23, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results for the fourth quarter and the full year ending December 2022. "In 2022, our team exceeded our strategic goals, achieving record HEPLISAV-B revenue, advancing our clinical pipeline and delivering orders of CpG 1018 adjuvant for the equivalent of hundreds of millions of COVID-19 vaccine doses," said Ryan Spencer, Chief Executive Officer of Dynavax. "Following a year of successful execution on our strategy, we are excited for 2023 and look forward to continuing our trend of significant and sustainable annual HEPLISAV-B revenue growth and overall advancement of our business focused on protecting patients worldwide from infectious diseases." 2023 FINANCIAL GUIDANCE Dynavax anticipates full-year 2023 revenue and operating expenses to be in the ranges below: HEPLISAV-B net product revenue between approximately $165 - $185 million Research and development expenses between approximately $55 - $70 million Selling, general and administrative expenses between approximately $135 - $155 million BUSINESS UPDATES HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] HEPLISAV-B vaccine is the first and only adult hepatitis B vaccine approved in the U.S. and EU that enables series completion with only two doses in one month. Hepatitis B vaccination is universally recommended for adults aged 19-59 in the U.S. HEPLISAV-B vaccine achieved record annual net product revenue of $125.9 million for 2022, compared to $61.9 million for 2021, representing annual growth of 104%. HEPLISAV-B market share in prioritized Integrated Delivery Networks (IDNs) and Clinics increased to approximately 47%, with total market share increasing to approximately 35%, up from approximately 33% and 25%, respectively, at the end of 2021. Dynavax believes it has begun to see a positive impact on HEPLISAV-B revenue from the expanded ACIP recommendation for adult hepatitis B vaccination which has the potential to expand the market to over $800 million by 2027 with HEPLISAV-B well-positioned to achieve a majority market-share. CpG 1018® Adjuvant Supply for COVID-19 Vaccines Dynavax has established a global portfolio of CpG 1018 adjuvant commercial supply agreements (CSAs) supporting the development of COVID-19 vaccines across a variety of vaccine platforms. CpG 1018 adjuvant achieved annual net product revenue of $587.7 million for 2022, up 57% compared to $375.2 million for 2021. Due to the successful execution on the pandemic commercial supply agreements and the resulting volume of partners' overall stockpile, coupled with unknowns about the trajectory of the COVID-19 pandemic, Dynavax believes it will have minimal to as little as zero CpG 1018 adjuvant net product revenues in 2023. Clinical Pipeline Dynavax is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant, which has demonstrated its ability to enhance the immune response with a favorable tolerability pro a wide range of clinical trials and real-world commercial use. Tetanus, diphtheria and pertussis (Tdap) vaccine program: In October, the Company presented adult and adolescent safety data from a Phase 1 clinical trial demonstrating the Tdap vaccine candidate was well tolerated without observed safety concerns. Immunogenicity in adults was consistent with the Company's expectations and support its plan to continue advancement of this clinical program. These clinical results were presented at ID Week 2022. Data from non-human primate challenge study is anticipated mid-2023. The Company plans to initiate a human challenge study by the end of 2023. Shingles vaccine program: In January 2023, the Company reported top line results from the Phase 1 clinical trial designed to evaluate an investigational shingles vaccine, utilizing different regimens of CpG 1018 adjuvant. The full Phase 1 data will be submitted for presentation at an upcoming medical meeting in the first half of 2023. The Company plans to initiate a Phase 1/2 study in early 2024 to evaluate various dose levels of glycoprotein E (gE). Plague vaccine candidate funded by the Defense Department (DoD): Part 1 of the Phase 2 clinical trial evaluating the immunogenicity, safety, and tolerability in adults of a plague (rF1V) vaccine candidate adjuvanted with CpG 1018 was successfully completed in January 2023. Both CpG 1018 adjuvanted arms met the Part 1 primary endpoint and demonstrated a greater than two-fold increase in antibodies over the alum adjuvanted control arm after two doses. The DoD has approved continuing to Part 2 using a bedside mix of CpG 1018 with the alum adjuvanted rF1V plague vaccine. FOURTH QUARTER AND FULL YEAR FINANCIAL HIGHLIGHTS Total Revenue. Total revenue for the fourth quarter of 2022 was $184.5 million, compared to $195.1 million for the fourth quarter of 2021. Total revenue for the full year 2022 was $722.7 million, compared to $439.4 million for the full year 2021. Product Revenue, Net. HEPLISAV-B® HEPLISAV-B vaccine product revenue, net was $34.9 million for the fourth quarter of 2022, compared to $17.2 million for the fourth quarter of 2021. HEPLISAV-B vaccine product revenue, net was $125.9 million for the full year 2022, compared to $61.9 million for the full year 2021, representing annual growth of 104%. CpG 1018® Adjuvant Supply for COVID-19 Vaccines CpG 1018 adjuvant product revenue, net was $147.2 million in the fourth quarter of 2022, compared to $177.4 million in the fourth quarter of 2021. CpG 1018 adjuvant product revenue, net was $587.7 million for the full year 2022, compared to $375.2 million for the full year 2021. Cost of Sales - Product. Cost of sales - product for the fourth quarter of 2022 increased to $77.5 million, compared to $74.0 million for the fourth quarter of 2021. Full year 2022 cost of sales - product was $262.2 million compared to $173.6 million for the full year 2021. The increase was due to higher sales volume for HEPLISAV-B and CpG 1018 adjuvant in 2022. Research and Development Expenses (R&D). R&D expenses for the fourth quarter of 2022 increased to $12.9 million, compared to $11.1 million for the fourth quarter of 2021. Full year 2022 R&D expenses were $46.6 million compared to $32.2 million for the full year 2021. The increase was primarily driven by continued investments in our product candidates utilizing CpG 1018 adjuvant through pre-clinical and clinical collaborations and additional discovery efforts. Selling, General, and Administrative Expenses (SG&A). SG&A expenses for the fourth quarter of 2022 increased to $31.0 million, compared to $29.2 million for the fourth quarter of 2021. Full year 2022 SG&A expenses were $131.4 million compared to $100.2 million for the full year 2021. The increase was primarily driven by higher compensation and related personnel costs and an overall increase in targeted commercial and marketing efforts to increase market share and maximize the Centers for Disease Control and Prevention's Advisory Committee of Immunization Practices (ACIP) universal recommendation. Net Income. GAAP net income was $67.7 million, or $0.53 per share (basic) and $0.45 per share (diluted) in the fourth quarter of 2022, compared to GAAP net income of $99.8 million, or $0.80 per share (basic) and $0.55 per share (diluted) in the fourth quarter of 2021. GAAP net income was $293.2 million, or $2.32 per share (basic) and $1.97 per share (diluted) for the full year 2022, compared to GAAP net income was $76.7 million, or $0.62 per share (basic) and $0.57 per share (diluted) for the full year 2021. Cash and Marketable Securities. Cash and marketable securities were $624.4 million as of December 31, 2022. Conference Call and Webcast Information Dynavax will host a conference call and live audio webcast on Thursday, February 23, 2023, at 4:30 p.m. (ET)/1:30 p.m. (PT). The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at . A replay of the webcast will be available for 30 days following the live event. To dial into the call, participants will need to register for the call using the caller registration link. It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call. Important U.S. Product Information HEPLISAV-B is indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older. For full U.S. Prescribing Information for HEPLISAV-B, click here. Important U.S. Safety Information (ISI) Do not administer HEPLISAV-B to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B. Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B. Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration. The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23% to 39%), fatigue (11% to 17%), and headache (8% to 17%). About Dynavax Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant with adjuvanted vaccine clinical programs for shingles and Tdap, and through global collaborations, currently focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza and universal influenza. For more information about our marketed products and development pipeline, visit and follow Dynavax on LinkedIn. Forward-Looking Statements This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to a number of risks and uncertainties. All statements that are not historical facts are forward-looking statements. Forward-looking statements can generally be identified by the use of words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "intend," "will," "may," "plan," "project," "potential," "seek," "should," "think," "will," "would" and similar expressions, or the negatives thereof, or they may use future dates. Forward-looking statements made in this document include statements regarding financial guidance, the development and potential approval of vaccines containing CpG 1018 adjuvant by us or by our collaborators, potential future sales of CpG 1018 adjuvant or HEPLISAV-B vaccine, the timing of initiation and completion of clinical studies and the publication of results. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including, the risk that actual demand for our products may differ from our expectations, risks related to the timing of completion and results of current clinical studies, risks related to the development and pre-clinical and clinical testing of vaccines containing CpG 1018 adjuvant, whether use of CpG 1018 adjuvant will prove to be beneficial in these vaccines, risks related to whether and when the quantity of CpG 1018 adjuvant actually purchased by vaccine companies will meet our expectations, as well as other risks detailed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2022 and periodic filings made thereafter, as well as discussions of potential risks, uncertainties and other important factors in our other filings with the U.S. Securities and Exchange Commission. These forward-looking statements are made as of the date hereof, are qualified in their entirety by this cautionary statement and we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. Information on Dynavax's website at is not incorporated by reference in our current periodic reports with the SEC. Contacts: Nicole Arndt, Investor Relations and Corporate Communications narndt@dynavax.com 510-665-7264 Derek Cole, President Investor Relations Advisory Solutions derek.cole@IRadvisory.com Company Codes: NASDAQ-SMALL:DVAX

Los Angeles, USA, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Herpes Zoster Pipeline Report: Current Therapies, Emerging Drugs, and Treatment Outlook Approximately 6+ key companies are developing therapies for Herpes Zoster treatment.  Curevo Vaccine has its drug candidates in the most advanced stage (Phase I). An increase in the prevalence of the disease and an increase in the elderly population will lead to cutting-edge technological developments for the effective treatment of the herpes zoster. DelveInsight’s “Herpes Zoster Pipeline Insight” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in the Herpes Zoster pipeline landscapes. It comprises Herpes Zoster pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Herpes Zoster therapeutics assessment by product type, stage, route of administration, and molecule type and highlights the inactive Herpes Zoster pipeline products. Some of the key takeaways from the Herpes Zoster Pipeline Report Get an overview of pipeline landscape @ Herpes Zoster Clinical Trials Analysis Herpes Zoster, also known as Shingles, is a localized, blistering, and painful rash caused by the varicella-zoster virus’s reactivation (VZV).  The first line of treatment for Herpes Zoster and the most widely used agents for zoster infection are antiviral agents such as Acyclovir, valacyclovir, and famciclovir. Herpes Zoster Emerging Drugs CRV-101 is an investigational adjuvanted subunit vaccine to indicate the Herpes Zoster prevention in older adults. It is a next-generation shingles vaccine candidate designed to maximize CMI protection by combining the gE protein antigen with its proprietary adjuvant. The vaccine is in Phase I clinical studies to prevent shingles in adults. A varicella-zoster virus vaccine (EG HZ) is a non-live, recombinant subunit vaccine being developed by EyeGene to prevent herpes zoster caused by the varicella-zoster virus (VZV). The vaccine combines a recombinant antigen, glycoprotein E (VZVgE), and CIA09, an adjuvant system. A Phase I clinical trial evaluating the EG-HZ vaccine has been completed. GLS-5100 is a DNA-based varicella-zoster virus vaccine encoding an antigen involved in virus latency. GLS-5100 induces no safety concerns and can be used in immunosuppressed persons. The vaccine is in the preclinical stage for the treatment of Herpes Zoster. For further information, refer to the detailed report @ Herpes Zoster Pipeline Therapeutics Scope of Herpes Zoster Pipeline Drug Insight ·       Herpes Zoster Therapies Late-stage (Phase III)  ·       Herpes Zoster Therapies Mid-stage (Phase II)·       Herpes Zoster Therapies Early-stage (Phase I) ·       Herpes Zoster Preclinical stage and Discovery candidates     ·       Discontinued and Inactive candidates ·      Immunostimulants·    Glycoprotein inhibitors·    Immediate early protein inhibitors ·       Gene therapy ·      Monoclonal Antibody ·     Small molecule ·      Peptides·      Polymer ·     Subretinal  ·      Parenteral ·      Oral·      Intravitreal·      Topical ·       Monotherapy·       Combination·       Mono/Combination Key Questions regarding Current Herpes Zoster Treatment Landscape and Emerging Therapies Answered in the Pipeline Report Table of Contents Get a customized pipeline report @ Herpes Zoster Drugs Pipeline Report Other Reports Browse Blog Posts About DelveInsightDelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.

CALGARY, Alberta, April 20, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today the publishing of an article titled: “Bromodomain and extraterminal protein inhibitor, apabetalone (RVX-208), reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro”, in Biomedicines, a high-impact scientific journal. The previously announced findings, made in collaboration with Dr. Dalia ElGamal’s research group at the University of Nebraska Medical Center (UNMC), Omaha, NE, have completed the peer-review process. The publication can be viewed using the following LINK. “We are proud to publish our findings that have come about as part of a second world class scientific collaboration on the beneficial impact of apabetalone in reducing COVID-19 infection of lung cells, the first collaboration demonstrated benefits to the heart,” said Donald McCaffrey, President and CEO of Resverlogix. “We believe apabetalone will prove to be a valuable tool in combatting the current pandemic and we are grateful for the contributions of researchers, such as Dr. ElGamal for answering our call for collaborations and in helping make that a reality.” Program Update Apabetalone is an investigational, phase 3 clinical candidate with safety data in more than 4,000 subjects. Resverlogix is advancing an open-label study to assess the safety and efficacy of apabetalone in the treatment of COVID-19, following a recent authorization from Health Canada. As previously announced, an article published on March 23, 2020 revealed the interaction between SARS-CoV-2 (COVID-19) protein E with BET proteins. Following this finding, Resverlogix put out a call for collaborations, resulting in multiple partnerships, and in parallel initiated in-house preclinical research to further characterize and investigate apabetalone’s efficacy in treating COVID-19 infection. The results of the collaborative research efforts have uncovered that apabetalone has the potential to combat COVID-19 through a unique dual mechanism. First, apabetalone treatment prevents SARS-CoV-2 from infecting human cells, and second it reduces the inflammation and cytokine storm response which can result in organ damage and long-term negative impacts. As a result of its dual mechanism and clinical safety record, several peer-reviewedpublications have shortlisted apabetalone as a clinical candidate for COVID-19. About Resverlogix Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. Apabetalone is the first therapy of its kind to have been granted US FDA Breakthrough Therapy Designation – for a major cardiovascular indication – to help facilitate a time-efficient drug development program including planned clinical trials and plans for expediting the manufacturing development strategy. BET inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile. Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX). Follow us on: Twitter: @Resverlogix_RVX LinkedIn: Investor Relations Email: ir@resverlogix.com Phone: 403-254-9252 Or visit our website: This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information related to apabetalone as a potential therapeutic for COVID-19 and upcoming clinical trials, and the potential role of apabetalone in the treatment of patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.